Ikerian’s Post

Interesting updates from across the #medicalimaging space, right at your finger tips 💡 Following SuperSonic Imagine's recent buy back from Hologic, Inc. after the 2019 acquisition of a 46% stake. Hologic, Inc. mammography system maker now puts in a huge $310M bid to acquire rival breast care company Endomag. Remember this is the second major acquisition in the breast care space following Lunit Global's proposed acquisition of Volpara Health at the end of 2023. Spotify to Neko Health, Daniel Ek's health business raised €60m for international expansion in July last year and now set to arrive in London, UK this summer. Their full-body scanning procedure takes 10-15 minutes and will set you back €250, but can you put a price on health? Neko Health has 20,000 patients on it's waiting list in Sweden. Staying in Sweden, Sectra's digital pathology solution together with Leica Biosystems Aperio GT 450 DX have received a 510(k) clearance by the FDA. This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, marking a significant step to standardisation in the field. #Radiology #Pathology #Mammography #FullBodyScan

3rd #StartupDrinks, hosted this time by OKKO Health, deepeye - preventing blindness and Visotec GmbH at #EURETINA to exchange among #founders + (young) #innovators about how to break into the #ophthalmic market and advance #retinalcare: - introductions to #KOL - discussing #FDA interactions - sharing best practices on communicating #clinicalbenefits - comparing #reimbursement pathways between countries - calculating #NHS time and cost savings - and many more actionable insights … #Startups & innovators mainly from the 🇬🇧🇩🇪🇦🇹, but also 🇨🇭🇮🇹🇪🇸 and even as far as 🇺🇸🇦🇺 participated as well as European Society of Retina Specialists (EURETINA)'s former president Alistair Laidlaw We gathered a “slightly” larger crowd than anticipated of people, but thanks to the quick reorganisation by Josefine Kelly and the flexibility of the Hilton staff we were accommodate everyone on the #roofterrace. Looking forward to our next #StartupDrinks at Association for Research in Vision and Ophthalmology (ARVO) 2025 in #SaltLakeCity University of Utah John A. Moran Eye Center. If you cannot wait, reach out to meet with a national cohort at one of the upcoming #ophthalmology #conference like #DOG24, #AAO24 in Chicago, or #DOC25. #EURETINA24 #EuropeanStartups #Europe #AIinHealthcare #RetinalTherapy #Innovation #Ophthalmology #deepeyeMedical #ARVO25

Ark Surgical Ltd., a pioneering medical device company within the www.intempo.ventures portfolio, has secured $1.1 million to advance safer surgical solutions tailored specifically for Women's Health. Sealed between December 2023 and January 2024, this investment marks a pivotal milestone for Ark Surgical as it pursues its mission to improve women's healthcare with safer surgical interventions. The infusion of funds will predominantly fuel the company's strategic expansion efforts in the United States, particularly in promoting its FDA-cleared tissue containment system, the #LapBox. Entities in this funding round include Intempo Ventures, #NGT3, the Israel Innovation Authority (IIA), and the Israel Ministry of Economy and Industry. Additionally, Ark Surgical has garnered support from a distinguished U.S.-based medical device group comprising seasoned physicians and executives renowned for their extensive expertise in the healthcare landscape. #LapBox containment system directly addresses the FDA's imperative to mitigate the risk of undiagnosed cancer dissemination during tissue morcellation, all while enhancing patient outcomes by facilitating minimally invasive alternatives to conventional, higher-risk open surgeries. Learn more in Femtech Insider > https://lnkd.in/dtnpAA7E #womenshealth #gynecology #medtech #healthcareinvestment #medicaldevices

✨ One week ago, the Digital Rheumatology Network meeting in Berlin opened its doors, and I was thrilled to be part of it! 🌐 Here's a quick dive into my takeaways: 🔍 The Journey of Adaptation: The road to integrating new digital technologies in rheumatology has just begun. Surprisingly, even the leaders in the field are yet to embrace digital therapeutics fully, with no German rheumatologist I met having prescribed a DTx to a significant number of patients. 👥 Dr. Matthias Zenker, MD raised a critical point about the scarcity of rheumatologists. The question is, are we fully grasping the urgency of the situation? 🤔 🤖 AI at its Dawn: The use of AI and LLM in rheumatology feels like the first few pages of an exciting novel. Currently, it's finding its place in streamlining practical and administrative tasks. Can't wait to see what the next chapters hold! 🚀 🤝 Co-Creation & Innovation: Time to shift gears from the traditional 'drug delivery and prescription' to collaborative partnerships. It's about crafting a digital future together through a build-measure-learn approach. And yes, we definitely need more designers to bridge the gap between patient needs and healthcare provider tools. 🌉 🎉 Vibrant Vibes: The atmosphere was nothing short of amazing - a cosy haven for an introvert like me! A heartfelt thank you to Thomas Hügle, Sina Reis-Balikcioglu, and the whole committee for crafting such an engaging event. Shoutout to PD Dr. Johannes Knitza MHBA, Mike Rosenbluth, Elena Nikiphorou, Vincenzo Venerito, Annette Thurah, Felix Lang, Barbara Bislawska Axnäs, Boris Leveque, Diana Girnita MD, PhD, Okan Ekinci, MD MBA, Baher Higazy, Thomas DAVERGNE and all the brilliant minds I met! 🗣️ Looking Ahead: I'm eager to see more voices from the RMD community next year. Perhaps, we could stir up the conversation with a session on co-creation or healthcare innovation? Here's to making 2025 even more impactful! 🚀 #DigitalRheumatology #HealthcareInnovation #PatientCare #AI #Rheumatology #CoCreation #LLM

We are thrilled that PulseSight has been selected as a finalist in this year’s LSX - partnering for Life Science eXecutives, European Lifestars Awards - Celebrating Life Science Leaders, in the Seed Raise of the Year category. An ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, we launched earlier this year with seed backing from Pureos Bioventures, #ND Capital and Korea Investment Partners (KIP), to advance our first-in-class therapies into clinical trials for age-related macular degeneration (#AMD) including geographic atrophy (#GA) secondary to dry AMD and wet AMD and., major diseases of the elderly and the third cause of blindness worldwide. We have assembled a highly experienced team, board and SAB and our series A capital raising to finance our programs through proof-of-concept human trials is underway. To find out more about the company and our programs visit www.pulsesight.com We are looking forward to networking with other finalists, investors and industry luminaries at The European Lifestars Awards Dinner at City Central Honourable Artillery Company London on Monday 18 November, where winners will be announced. The full line up of finalist in all categories and across five European regions are highlighted here https://lnkd.in/dNeDbkCx. #awards #genetherapy #opthalmology #drugdevelopment #blindness #retinaldisease

Thank you, Modern Retina, for interviewing our Medical Advisor, Durga S. Borkar, MD, MMCi, about our #RWD research, in collaboration with Genentech and Bausch + Lomb, that was presented during #RetinaWorldCongress. Dr. Borkar also shared how our Qdata Geographic Atrophy module is unlocking new research possibilities by linking EHR + imaging data for a complete view of a patient's healthcare journey. https://hubs.la/Q02yBRR-0

Some exciting funding news for one of our 2024 Future Club companies aiSight.ai. AI-Sight – the University of Liverpool #AI diagnostic technology spin-out based at Sci-Tech Daresbury – has successfully concluded its seven-figure equity funding round from experienced healthcare industry figures and investors. This funding round will support MHRA approval and Class 2 certification for AI-Sight’s full diagnostic platform, as well as its launch in the UK and internationally. The platform is designed to improve patient outcomes, with additional benefits that promote efficiency in public health systems and ensure human resources are allocated to the areas of greatest need. The funders, committed to developing innovation and business in the North West of England, include Sir Michael Bibby (Chairman of the Bibby Line Group and Hon PhD, University of Liverpool), Phil Kirby (former Managing Director of InHealth Intelligence), Pitalia Capital (the family office of Anil Pitalia, Founder of SpaMedica, ophthalmology specialists) and Deepbridge Capital. This follows the Class 1 medical device certification of AI-Sight’s first commercial product. The AI software device is designed to support training and diagnostic decision-making by human graders of diabetic retinopathy in retinal scans. Emma Nolan Anthony Mtitimila Vicky Hincks Matt Biagetti Amy Farrington Emmanuel Dupuis Prof Richard Harding Francis Lee #mhra #AI #medicaldevice #LCRInnovation https://lnkd.in/eqwGGzB8

It is the most fascinating technological change to me right now: The rise of 𝐀𝐈 𝐢𝐧 𝐨𝐩𝐡𝐭𝐡𝐚𝐥𝐦𝐨𝐥𝐨𝐠𝐲. 🧠 From diagnostics to therapeutics and monitoring - it just touches all aspects of the workflow. The positioning of different players in the market is also super interesting to understand: start-ups (PeriVision, etc. ), clinics (Moorfields Eye Hospital, London, etc.), ambulatory centers (Chu Vision Institute, etc.), industry giants (Alcon, etc.), and tech giants (Alphabet Inc., etc.). Remarkable MedTech published a short first article about the subject—link in the comments below. #AI #ophthalmology

Eden (YC S18) has raised $10 million in Series A funding to improve radiology diagnoses globally. A convergence of factors, including increasing demand for imaging studies and COVID-related burnout, is exacerbating a global shortage of radiologists. According to the World Health Organization, the proportion of the world’s population over 60 will be 22% by 2050, nearly double that of 2015. This older population requires more imaging, but it has significantly outpaced the number of radiologists entering the field in recent years. The Mexico City startup, founded by Julián Ríos Cantú, Raymundo González Leal, and Antonio Torres, is addressing this issue by using LLMs to help radiologists process vast amounts of medical data. Its cloud-based system enables radiologists to connect to the platform and verify diagnoses remotely, allowing for faster diagnoses and enabling them to help more patients. Today, Eden is used by 75% of radiologists in Mexico. Initially focused on Latin America, Eden currently processes over 6 million studies annually, serving over 1,500 institutions across 17 countries. Congrats to the team on the Series A! https://lnkd.in/gDUSZRsN

Have you heard of the HyperProbe Project? Hyperprobe develops a a new optical imaging device providing enhanced information to #neurosurgeons in brain #cancer surgeries. This cutting- edge technology will be based on #hyperspectral #imaging and will not only be able to distinguish cancerous and healthy cells with a high level of accuracy and sensitivity during surgery but will also be non-invasive, cost-effective and transportable! Learn more at #ECR2024 on March 1st, in the session 'From pixels to probes: unveiling the potential of integrated photonics in medical imaging' where Luca Giannoni from the Università degli Studi di Firenze will present the latest results! Cannot make it to #ECR24 this year? You can access our sessions online, free of charge! For more info, click here: 👉 https://lnkd.in/dzWnf6W8 #HorizonEU #cancerresearch #photonics #neurology